A

Amgen

Makes biotech medicines for serious illnesses

Global Category Associate Director Data Analytics and AI Platforms

Full-TimeUpdated on 10/22/2026
No salary listed
Expert
Bachelor's, Master's, PhD
Hyderabad, Telangana, India
In Person
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • Familiarity with procurement platforms such as Ariba, ERP systems, and advanced analytics tools to support decision-making and process automation.
  • Experience leading large, cross-functional teams and managing complex global projects in a matrixed environment.
  • Experience managing analytics and AI/ML software procurement.
  • Understanding of cloud data ecosystems, including Snowflake, Databricks, and AWS, Azure, or Google AI.
  • Strong analytical skills and ability to assess large data sets and supplier performance.
  • Doctorate degree and 14 years of Global Strategic Sourcing, Procurement, or Commercial experience; or a master’s degree and 15 to 17 or more years of such experience; or a bachelor’s degree and 17 to 18 years of such experience.
  • Two years of managerial experience directly managing people and/or leading teams, projects, or programs.
Responsibilities
  • Lead and evolve the category strategy for Data Analytics and AI Platforms, enabling data-driven insights across R&D, Commercial, Operations, and G&A functions.
  • Partner with Digital, Data Science, and IT leaders to standardize platforms such as data lakes, analytics, and AI/ML environments.
  • Evaluate emerging suppliers in data, AI, and predictive analytics and incorporate innovation responsibly.
  • Design contracts that balance access to innovation with compliance, governance, and cost efficiency.
  • Develop multi-year sourcing roadmaps to ensure data and AI platforms meet enterprise growth and compliance needs.
  • Provide strategic oversight as the global lead for Software category and sourcing, aligning category strategies with Amgen’s business needs and advising on procurement initiatives aligned with organizational objectives.
  • Guide collaboration across cross-functional teams and regional stakeholders so procurement strategies address organizational needs and are implemented effectively.
  • Ensure Software procurement activities comply with regulatory, contractual, and operational risk requirements; partner with Legal, Compliance, Data Privacy, and Cybersecurity teams on risk mitigation and alignment with best practices.
  • Collaborate with Strategic Sourcing peers on the strategic approach to complex Software contract negotiations, providing guidance and ensuring appropriate processes and frameworks for RFPs, supplier evaluations, and contract development.
  • Activate procurement resources toward category priorities while managing stakeholder expectations.
  • Analyze internal demand using Business Partner Management processes, external market data, spend, and specifications to produce a category plan aligned with business objectives and cost reduction and sourcing initiatives.
  • Drive supplier performance, manage risk, and deliver sustained value across the global professional services landscape.
Desired Qualifications
  • Software global category management experience with a proven record of executive business partnering, leading change, and enterprise activation of sourcing initiatives based on expert marketplace knowledge.
  • Deep understanding of category management principles, supplier relationship management, and contract lifecycle management.
  • Strong financial, legal, and contractual fluency to navigate sales services agreements and deliver business-aligned outcomes.
  • Track record of driving innovation in category strategy development, supplier engagement models, and internal stakeholder partnerships.
  • Ability to communicate complex category strategies, influence senior stakeholders, and manage change across functions and regions.
  • Ability to identify underlying business needs proactively and craft strategic solutions across the Software landscape.
  • Ability to use spend analytics and benchmarking to inform category strategies and uncover value opportunities.
  • Understanding of regulatory landscapes and ability to navigate and manage compliance requirements.
  • Ability to articulate a forward-looking category vision for Software and rally stakeholders around a shared, value-driven agenda.
  • Expertise in AI ethics, governance, and responsible AI frameworks.
  • Ability to align sourcing strategies with R&D and Commercial data priorities.
  • Proven ability to evaluate and benchmark AI and analytics platforms.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.